Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Can Semaglutide Bind Tighter to GLP-1R?

Wei Li * ORCID logo
Version 1 : Received: 23 July 2020 / Approved: 24 July 2020 / Online: 24 July 2020 (11:58:41 CEST)

How to cite: Li, W. Can Semaglutide Bind Tighter to GLP-1R?. Preprints 2020, 2020070582 (doi: 10.20944/preprints202007.0582.v1). Li, W. Can Semaglutide Bind Tighter to GLP-1R?. Preprints 2020, 2020070582 (doi: 10.20944/preprints202007.0582.v1).

Abstract

Semaglutide is a glucagon-like peptide 1 analog used for the treatment of patients with type 2 diabetes mellitus. With 94% sequence similarity to human GLP-1, semaglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist, which binds directly to GLP-1R, causing various beneficial downstream effects that reduce blood glucose. Practically, it is favourable for semaglutide to bind not just directly, but also tighter, to its receptor GLP-1R. Therefore, incorporating currently available experimental structural data of semaglutide-GLP-1R, this short article reports for the first time that biophysically, semaglutide is able to bind tighter to GLP-1R with just a simple Val27-Arg28 exchange in its peptide backbone.

Subject Areas

Semaglutide; GLP-1R; Interfacial Biophysics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.